Efficacy

Alunbrig (Brigatinib) Efficacy in Lung Cancer

Alunbrig (brigatinib) is a targeted therapy approved by the U.S. Food and Drug Administration (FDA) for the treatment of non-small cell lung cancer (NSCLC) with a specific genetic mutation. It is specifically indicated for patients who have anaplastic lymphoma kinase (ALK)-positive metastatic NSCLC who have progressed on or are intolerant to crizotinib. Brigatinib is a tyrosine kinase inhibitor that targets and inhibits ALK, which can drive the growth of cancer cells in some lung cancers.

Clinical trials have demonstrated the efficacy of Alunbrig in this patient population. In a pivotal phase 2 trial, brigatinib showed a high overall response rate in patients who had progressed on crizotinib. Additionally, the progression-free survival (PFS) rates observed with brigatinib treatment were promising, indicating a significant delay in the progression of the disease. The efficacy of Alunbrig was further supported by durable responses and a manageable safety profile.

Libtayo (Cemiplimab) Efficacy in Lung Cancer

Libtayo (cemiplimab) is a type of immunotherapy known as a checkpoint inhibitor, specifically an anti-PD-1 antibody. The FDA approved Libtayo for the first-line treatment of patients with NSCLC whose tumors express PD-L1 on at least 50% of their cells and who do not have EGFR, ALK, or ROS1 aberrations. Cemiplimab works by enhancing the body's immune response against cancer cells, allowing the immune system to detect and destroy them more effectively.

In clinical studies, Libtayo has shown a significant improvement in overall survival compared to chemotherapy in patients with advanced NSCLC with high PD-L1 expression. The treatment has also demonstrated a higher response rate and longer progression-free survival compared to chemotherapy. These results establish cemiplimab as an effective first-line treatment option for patients with advanced PD-L1 positive NSCLC. The use of Libtayo has expanded the arsenal of treatments available for lung cancer, offering hope for better outcomes in a subset of patients with this challenging disease.